EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers

BACKGROUND: A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Eph receptors have been shown to play essential roles in tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhen, Wu, Hao-Xiang, Lin, Wu-Hao, Wang, Zi-Xian, Yang, Lu-Ping, Zeng, Zhao-Lei, Luo, Hui-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852135/
https://www.ncbi.nlm.nih.gov/pubmed/33526018
http://dx.doi.org/10.1186/s12916-020-01899-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852135/
https://www.ncbi.nlm.nih.gov/pubmed/33526018
http://dx.doi.org/10.1186/s12916-020-01899-x

Ejemplares similares